TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC ...

According to Benzinga Pro, TransCode Therapeutics's peer group average for short interest as a percentage of float is 3.92%, ...

Shares of TransCode Therapeutics stock opened at $3.85 on Wednesday. The business has a fifty day simple moving average of $395.55 and a 200-day simple moving average of $565.72. TransCode ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and TransCode Therapeutics (RNAZ – Research Report ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap biotech company with a market capitalization of $3.3 million and trading near its 52-week low, has received approval from its ...

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap biotech company with a market capitalization of $3.3 million and trading near its 52-week low, has received approval from its Safety ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...